HPK1 Inhibitor Compounds for Selective Immune Modulation
Solution Overview
Problem
There is a need for HPK1 inhibitory compounds to modulate HPK1 activity for treating diseases or disorders, particularly autoimmune conditions and cancer, as HPK1 plays dual roles in immune regulation and its dysregulation is associated with enhanced T- and B-cell activation and autoimmunity.
Innovation Solution
Development of compounds represented by Formulae (I-0), (I-1), (I), (II), (II-1), (II-2), or (II-2′), which inhibit HPK1 activity, including pharmaceutically acceptable salts and stereoisomers, to regulate immune responses and treat conditions such as cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HPK1 activity is inhibited to treat cancer, then immune response is enhanced, but immune dysregulation and autoimmune disorders may be exacerbated
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (Formulae I-0, I-1, I-2, I, II, II-1, II-2, II-2') that selectively modulate HPK1 activity. By optimizing chemical parameters such as substituent groups (R1, R2, R3, Ra, Rb, Rc, R11, R12) and molecular properties, the invention achieves selective inhibition of HPK1 in cancer cells while minimizing off-target effects that could trigger autoimmune responses.
Solution Approach 2:
The patent applies local quality by designing compounds that exhibit selective activity profiles. The molecular structures are engineered to interact specifically with HPK1 in the context of cancer pathology, allowing differential modulation of immune responses - enhancing anti-tumor immunity while preserving regulatory mechanisms that prevent autoimmune disorders. This selectivity is achieved through specific structural features that target cancer-associated HPK1 signaling pathways.
2Adaptability or versatility
If specific HPK1 inhibitor compounds are developed to modulate immune responses, then cancer treatment options are expanded, but drug development complexity increases
Solution Approach 1:
The patent achieves universality by developing a series of compounds with core structural motifs that can be systematically modified to target HPK1 across different cancer types. The compounds of Formulae I-0, I-1, I-2, I, II, II-1, II-2, and II-2' represent a unified chemical series that can be adapted for treating breast, colorectal, lung, ovarian, and pancreatic cancers, reducing development complexity through platform-based design.
Solution Approach 2:
The patent applies segmentation by dividing the complex HPK1 inhibition task into manageable structural components. The compounds are designed with distinct functional regions (e.g., heteroaryl/heterocyclyl groups R, substituents R1-R12) that can be independently optimized. This modular approach allows systematic exploration of structure-activity relationships without overwhelming complexity.
Data Source
AI summary
Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.



